Acquisitions, Research and Development and Collaborative Arrangements, and Equity-Method Investments - Resarch and Development and Collaborative Arrangements (Details) patient in Thousands	1 Months Ended				3 Months Ended
	Jan. 31, 2016 USD ($)	Jul. 31, 2015 study patient	Mar. 31, 2015 USD ($)	Feb. 28, 2015 USD ($)	Apr. 03, 2016 USD ($)
RPI Finance Trust [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development arrangement, amount	$ 300,000,000
Research and development arrangement, contingent payments, maximum	$ 250,000,000
Research and development arrangement, term	7 years
Research and development arrangement, percentage of costs to be reimbursed (up to)	100.00%
Funding to offset costs incurred under research and development arrangement					$ 8,800,000
OPKO Health, Inc. [Member] | Collaborative Arrangement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront payments and milestone payments				$ 295,000,000
Contingent collaborative arrangement payments				$ 275,000,000
Eli Lilly & Company (Lilly) [Member] | Collaborative Arrangement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Number of studies | study		6
Number of patients | patient		7
Deferred Revenue [Member] | Eli Lilly & Company (Lilly) [Member] | Collaborative Arrangement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront payments received			$ 200,000,000